The primary objective is to safely determine if the investigators can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled the investigators will draw blood and urine for novel and standard biomarkers. The investigators are attempting to determine if these biomarkers can forecast the course of AKI (need for dialysis, death and renal recovery). The investigators seek to determine how well physicians caring for those with AKI can predict the clinical course compared to these novel biomarkers of AKI and if there is an association between clinical course and 3 year patient outcomes.
AKI is a very common disease in the setting of critical illness and carries an extremely high morbidity and mortality rate (over 50%). Currently there are no FDA approved therapeutic agents for the treatment of AKI. There is limited prospective evidence to guide nephrologists in terms of which patients will progress to more severe AKI in the setting of early AKI. Similarly, there is no evidence to guide nephrologists in terms of which patients will completely recover their renal function after AKI. Thus we need to know very early in the course of AKI which patients will progress and go on to require renal replacement therapy (RRT). Additionally we will investigating the long term patient outcomes, 2-3 years after the index AKI admission.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
96
dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
University of California-San Francisco
San Francisco, California, United States
George Washington University
Washington D.C., District of Columbia, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins Medicine
Baltimore, Maryland, United States
Progression to Stage 3 AKI
The number of patients who progressed to Stage 3 during the time of observation
Time frame: within 7 days of furosemide administration
Receipt of Renal Replacement Therapy (RRT)
The number of patients who received renal replacement therapy (Dialysis)
Time frame: within 7 days of furosemide administration
Death
Inpatient mortality
Time frame: During the index hospital stay, an average of 17 days, until hospital discharge, or until death, whatever occurs first
Length of Intensive Care Unit (ICU) Stay
duration if ICU stay for all patients
Time frame: During the index hospital stay, an average of 9 days, until ICU discharge, or until death, whatever occurs first
Length of Hospital Stay
duration of the total hospital Stay for all patients
Time frame: During the index hospital stay, an average of 17 days, until hospital discharge, or until death, whatever occurs first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.